DAVID THOMAS HARRISON DO
Prescription History 1255396255
Colon & Rectal Surgery in Indianapolis, IN

NPI Status: Active since April 20, 2006

Contact Information

3660 GUION RD
STE 330
INDIANAPOLIS, IN
ZIP 46222
Phone: (317) 923-1033
Fax: (317) 927-7426

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DAVID THOMAS HARRISON DO, an active Colon & Rectal Surgery specialist practicing in Indianapolis, IN. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 86 documented patient claims. Among these therapy options, the most frequently utilized medication is Dicyclomine Hcl, which accounts for 57 claims alone.

Medication Index

No matching medications currently found on file.

Dicyclomine Hcl

Generic Formulation: Dicyclomine HclSpecialty: Colorectal Surgery (Proctology)
Provider Metrics Summary
Total Claims 57
30-Day Fills 118.9
Days Supply 3,553
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills44.3
Peer Average Days Supply1,206
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 96.6% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,947.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.17

State Avg Cost Per Claim

$30.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Loperamide

Generic Formulation: Loperamide HclSpecialty: Colorectal Surgery (Proctology)
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
IN State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.9
Peer Average Days Supply385
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $265.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.12

State Avg Cost Per Claim

$25.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.

Therapeutic Applications

See also Warning section. This medication is used to treat sudden diarrhea (including traveler's diarrhea). It works by slowing down the movement of the gut. This decreases the number of bowel movements and makes the stool less watery. Loperamide is also used to reduce the amount of discharge in patients who have undergone an ileostomy. It is also used to treat on-going diarrhea in people with inflammatory bowel disease. Loperamide treats only the symptoms, not the cause of the diarrhea (such as infection). Treatment of other symptoms and the cause of the diarrhea should be determined by your doctor.

Mesalamine

Generic Formulation: MesalamineSpecialty: Colorectal Surgery (Proctology)
Provider Metrics Summary
Total Claims 17
30-Day Fills 41.0
Days Supply 1,189
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills40.5
Peer Average Days Supply1,189
Conservative Utilization

This provider writes prescriptions for this formulation 26.1% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,298.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$723.47

State Avg Cost Per Claim

$708.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Therapeutic Applications

This medication is used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain. Mesalamine belongs to a class of drugs known as aminosalicylates. It works by decreasing swelling in the colon.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DAVID THOMAS HARRISON DO provides transparency into local medical care patterns within Indianapolis, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Colon & Rectal Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.